Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Metrics to compare | TYRA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTYRAPeersSector | |
---|---|---|---|---|
P/E Ratio | −6.0x | −4.1x | −0.5x | |
PEG Ratio | −2.84 | 0.03 | 0.00 | |
Price/Book | 1.8x | 3.7x | 2.6x | |
Price / LTM Sales | - | 9.4x | 3.2x | |
Upside (Analyst Target) | 171.2% | 202.7% | 41.2% | |
Fair Value Upside | Unlock | 12.4% | 6.2% | Unlock |